

# METabolic EXplorer: Update on third-quarter 2010 activity

**Clermont-Ferrand, France, 4 November 2010** – METabolic Explorer, a green chemistry company that specializes in the development of bioprocesses for the production of chemical compounds used in a wide range of everyday products (textile fibres, paints, solvents, animal feed supplements, adhesives, etc.), today updated investors on its third-quarter 2010 activity.

The vagaries of the calendar have caused to company to disclose details of its third-quarter activity today, Thursday November 4<sup>th</sup>, 2010.

METabolic EXplorer would remind editors that a press conference, announced on Tuesday November 2<sup>nd</sup>, has been called for tomorrow, Friday November 5<sup>th</sup>, to provide a complete overview of company activity and in particular of its latest commercial developments (attendance at the press conference is restricted to journalists, financial analysts and institutional investors).

The present press release therefore only contains details of important financial data for the third quarter of 2010.

### Q3: Main financial data

#### Turnover for the period

(€ 000s)	2010	2009
1 <sup>st</sup> quarter	0	0
2 <sup>nd</sup> quarter	0	900
3 <sup>rd</sup> quarter	600	0
9-month turnover	600	900

Over the first three quarters of the 2010 accounting period, METabolic EXplorer recorded turnover of €600,000. This was generated by licence income from two processes (Glycolic Acid and L-Methionine) developed under a partnership agreement. The contract income is paid on achieving agreed project targets and as such may vary considerably from one quarter to another.

### **Cash and Equivalent**

As at September 30<sup>th</sup>, 2010 the company had gross cash and equivalent of €40.2 million.

#### About METabolic EXplorer - www.metabolic-explorer.com

METabolic EXplorer is a biological chemistry company which was incorporated in 1999. Its goal is to help industrial businesses deal with the heralded "end of oil", so that they can continue to manufacture but in a sustainable way.

Based on the tried and tested principle of industrial fermentation, METabolic Explorer's solutions circumvent the problems posed by today's burdensome and expensive petrochemical processes via the use of a wide range of renewable, sustainable raw materials. By optimizing the metabolic yield of non-pathogenic bacteria in a contained, controlled environment, the company facilitates the production of chemical compounds used in a wide range of everyday goods (textile fibres, paints, solvents, plastics and animal feed).

METabolic EXplorer is currently focusing its alternative biological solutions on the production of five compounds that together have an estimated, annual, end-market value of €11 billion. The company's strategy will be implemented in two ways: either through the creation of manufacturing plants in strategic geographic locations, or via limited-exclusivity industrial partnerships as part of joint-ventures.

METabolic Explorer, based in Clermont-Ferrand, France, is listed on EURONEXT PARIS (EURONEXT C, METEX) and features in the SBF 250 and CAC Small 90 indexes.

Get free financial information on METabolic EXplorer by registering with <a href="https://www.metabolic-explorer.com">www.metabolic-explorer.com</a> or <a href="https://www.actus-finance.com">www.actus-finance.com</a>.

#### Media and shareholder contacts

## **ATTITUDE Corporate**

Eric de Lambert

E-mail: <a href="mailto:edelambert@attitude-corporate.com">edelambert@attitude-corporate.com</a>
Tel.: +33 (0)1 4970 4341 / +33 (0)6 2529 0658

Emmanuelle Lapeyre

E-mail: <u>elapeyre@attitude-corporate.com</u>
Tel.: +33 (0)1 4970 4343 / +33 (0)6 1588 6209

# Investor and analyst contacts

#### **Actus Finance**

Jérôme Fabreguettes-Leib

Email: jfl@actus.fr

Tel.: +33 (0)1 7735 0436

This communication includes forward-looking information which is subject to risks and uncertainties. The potential development of the company could be substantially different from that anticipated in this press release because of the various risk factors which are described in the company's Listing Prospectus.